Want to join the conversation?
$AGN said cash flow from operations in 2Q16 was $1.4Bil. Excluding adjustments, primarily recent R&D acquisitions and integration expenses, cash flow from operations was $1.85Bil. US specialized therapeutics revenue was $1.5Bil for 2Q16, up 11% from 2Q15. US general medicine revenue was $1.45Bil.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?